European First As Vertex’s CRISPR/Cas9 Gene Therapy Casgevy Gets English Funding

Casgevy, the world’s first CRISPR gene editing therapy, is the second drug to be accepted onto a managed access scheme via England’s Innovative Medicines Fund, offering a new treatment for patients with transfusion-dependent beta thalassemia.